Bliss Gvs Pharma Ltd vs Ipca Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 10, 2026

Key Highlights

The Latest Trading Price of Bliss GVS Pharma Ltd is ₹ 423.7 as of 10 Jun 15:30 . The P/E Ratio of Bliss GVS Pharma Ltd changed from 14.9 on March 2021 to 14.7 on March 2025 . This represents a CAGR of -0.27% over 5 yearsThe P/E Ratio of Ipca Laboratories Ltd changed from 21.2 on March 2021 to 51.6 on March 2025 . This represents a CAGR of 19.47% over 5 years The Market Cap of Bliss GVS Pharma Ltd changed from ₹ 1018 crore on March 2021 to ₹ 1238 crore on March 2025 . This represents a CAGR of 4.00% over 5 yearsThe Market Cap of Ipca Laboratories Ltd changed from ₹ 24137 crore on March 2021 to ₹ 38088 crore on March 2025 . This represents a CAGR of 9.55% over 5 years The revenue of Bliss GVS Pharma Ltd for the Mar '26 is ₹ 268.18 crore as compare to the Dec '25 revenue of ₹ 236.71 crore. This represent the growth of 13.29% The revenue of Ipca Laboratories Ltd for the Mar '26 is ₹ 2482 crore as compare to the Dec '25 revenue of ₹ 2430 crore. This represent the growth of 2.13% The ebitda of Bliss GVS Pharma Ltd for the Mar '26 is ₹ 55.63 crore as compare to the Dec '25 ebitda of ₹ 50.73 crore. This represent the growth of 9.66% The ebitda of Ipca Laboratories Ltd for the Mar '26 is ₹ 531.79 crore as compare to the Dec '25 ebitda of ₹ 571.19 crore. This represent the decline of -6.9% The net profit of Bliss GVS Pharma Ltd changed from ₹ 22.11 crore to ₹ 37 crore over 8 quarters. This represents a CAGR of 29.36% The net profit of Ipca Laboratories Ltd changed from ₹ 198.98 crore to ₹ 309.4 crore over 8 quarters. This represents a CAGR of 24.70% The Dividend Payout of Bliss GVS Pharma Ltd changed from 7.64 % on March 2021 to 7.64 % on March 2025 . This represents a CAGR of 0.00% over 5 yearsThe Dividend Payout of Ipca Laboratories Ltd changed from 8.9 % on March 2021 to 15.59 % on March 2025 . This represents a CAGR of 11.86% over 5 years .

About Bliss GVS Pharma Ltd

Bliss GVS Pharma Limited was originally incorporated as a Private Limited Company in the name of Bliss Chemicals & Pharmaceuticals India Private Limited in 1984.
The status converted into a Public Limited Company and the name of the Company was changed to Bliss Chemicals & Pharmaceuticals India Limited and further to Bliss GVS Pharma Limited on May 12, 2006. The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
The Company has its manufacturing facility at Palghar which is WHO GMP approved.
The business operates five cutting-edge production facilities that adhere to WHO-GMP, EU-MP, ISO 14001 and OHSAS 45001 standards. The company commenced its business in 1985.
In 1994 the company introduced a new pharmaceutical product VAGID. During the financial year ended 31 March 2014, Bliss GVS Pharma's R&D center, received approval from Government of India's Department for Scientific & Industrial Research (DSIR).

About Ipca Laboratories Ltd

Ipca Laboratories Limited (IPCA) was incorporated on 19 October, 1949 under the name of 'The Indian Pharmaceutical Combine Association Limited.' Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 API's covering various therapeutic segments.
The products of the Company are now sold in over 100 countries across the globe.
The Company has 18 manufacturing units in India manufacturing API's and formulations for the world market. Ipca's APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries.

FAQs for the comparison of Bliss GVS Pharma Ltd and Ipca Laboratories Ltd

Which company has a larger market capitalization, Bliss GVS Pharma Ltd or Ipca Laboratories Ltd?

Market cap of Bliss GVS Pharma Ltd is 4,482 Cr while Market cap of Ipca Laboratories Ltd is 41,461 Cr

What are the key factors driving the stock performance of Bliss GVS Pharma Ltd and Ipca Laboratories Ltd?

The stock performance of Bliss GVS Pharma Ltd and Ipca Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bliss GVS Pharma Ltd and Ipca Laboratories Ltd?

As of June 10, 2026, the Bliss GVS Pharma Ltd stock price is INR ₹423.7. On the other hand, Ipca Laboratories Ltd stock price is INR ₹1634.25.

How do dividend payouts of Bliss GVS Pharma Ltd and Ipca Laboratories Ltd compare?

To compare the dividend payouts of Bliss GVS Pharma Ltd and Ipca Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.